Vyjuvek in Bahrain

Vyjuvek - overview

Vyjuvek (beremagene geperpavec) is manufactured by Krystal and indicated for Dystrophic epidermolysis bullosa. It is a Topical gene therapy (HSV-1) approved by the US FDA in 2023 and may be accessible to patients in Bahrain through a Named Patient Program or personal-import pathway.

Access in Bahrain

Bahrain's NHRA accepts named-patient import requests for rare-disease and specialty drugs not registered locally.

How Reserve Meds coordinates access in Bahrain

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Bahrain-specific eligibility.
3. Treating physician in Bahrain issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Vyjuvek from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Bahrain.

Typical timeline for Bahrain

End-to-end, most requests are completed in 2-6 weeks. Bahrain's tier 2 regulatory maturity typically supports moderate processing times.

What patients and physicians in Bahrain ask

• Is the pathway legal in Bahrain? Yes - it operates under Bahrain's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Bahrain able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Vyjuvek in Bahrain

Request Vyjuvek